The company has successfully commercialized the world's first antisense
drug and has 11 antisense
drugs in development to treat metabolic, cardiovascular and inflammatory diseases, and cancer.
Although researchers have been conducting laboratory and animal tests of antisense
compounds for about a decade, clinical data are just starting to roll in at scientific meetings.
AVI's proprietary antisense
chemistry has pharmaceutically important properties that are complementary to our existing technology," said Larry J.
Mark Diamond, CEO of Antisense
commented: "Although a drug's efficacy is typically not established until completion of Phase II clinical trials, this "proof of concept" study serves as a relatively inexpensive and efficient method of indicating the activity of ATL1101, while providing valuable data.
The researchers hope that the antisense
molecules will kill any leukemia cells that stow away in the transplant material, says Bishop.
AVI also has three ongoing Cooperative Research and Development Agreements (CRADAs) with various government agencies underway to test its antisense
drugs against a variety of infectious viruses:
Canada's affirmation of Enzo's rights to our pioneering work in genetic antisense
will allow us to move forward with this technology's promising applications, such as the Enzo-sponsored HIV clinical trial now underway in the U.
At the University of Nebraska Medical Center in Omaha, Eliel Bayever and his colleagues have conducted a preliminary evaluation of one type of antisense
in 11 people suffering from either an acute or premalignant form of myelogenous leukemia.
We believe the presence and persistence of each of the three NEUGENE drugs in the CSF after a single administration suggest potentially unique therapeutic applications for this class of antisense
drugs," said Dr.
Theologis' group used antisense
genetics to cut production of ethylene to such an extent that green tomatoes remained on the vine for as long as five months, ripening only to a pale orange.
AVI's proprietary NEUGENE antisense
drug candidates have demonstrated efficacy in preclinical studies against SARS coronavirus, West Nile virus (WNV), hepatitis C virus (HCV), dengue virus, Ebola virus and Marburg virus.
The researchers found that the arteries of rats treated with the antisense
therapy contained no detectable levels of c-myb RNA, while the arteries of rats treated with a control compound had high levels of the substance.
We are fortunate that NEUGENE antisense
technology provides flexibility for clinical protocol modification.
Recently, however, antisense
has blossomed into a high-stakes, big-bucks specialty, envisioned by its supproters as a revolutionizing force in clinical pharmacology.
Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE([R]) antisense
technology against influenza A and E.